7.73
price up icon0.78%   0.06
after-market After Hours: 7.72 -0.01 -0.13%
loading
Enanta Pharmaceuticals Inc stock is traded at $7.73, with a volume of 80,071. It is up +0.78% in the last 24 hours and up +8.57% over the past month. Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
See More
Previous Close:
$7.67
Open:
$7.7
24h Volume:
80,071
Relative Volume:
0.49
Market Cap:
$165.24M
Revenue:
$66.59M
Net Income/Loss:
$-104.93M
P/E Ratio:
-1.5616
EPS:
-4.95
Net Cash Flow:
$-96.48M
1W Performance:
+9.03%
1M Performance:
+8.57%
6M Performance:
+39.53%
1Y Performance:
-48.43%
1-Day Range:
Value
$7.70
$7.845
1-Week Range:
Value
$7.10
$8.11
52-Week Range:
Value
$4.09
$15.92

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
Name
Enanta Pharmaceuticals Inc
Name
Phone
617 607 0800
Name
Address
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
Employee
131
Name
Twitter
@EnantaPharma
Name
Next Earnings Date
2025-02-10
Name
Latest SEC Filings
Name
ENTA's Discussions on Twitter

Compare ENTA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
7.73 163.96M 66.59M -104.93M -96.48M -4.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-09-23 Downgrade JP Morgan Neutral → Underweight
Aug-08-23 Downgrade Jefferies Buy → Hold
Dec-09-22 Initiated H.C. Wainwright Buy
Jul-06-22 Upgrade Evercore ISI In-line → Outperform
Jun-01-22 Upgrade Evercore ISI Underperform → In-line
Oct-07-21 Initiated Jefferies Buy
Sep-09-21 Initiated SVB Leerink Mkt Perform
Jan-29-21 Upgrade JP Morgan Underweight → Neutral
Nov-24-20 Initiated Evercore ISI Underperform
Aug-28-20 Resumed ROTH Capital Buy
Aug-26-20 Initiated Piper Sandler Overweight
Jul-27-20 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Mar-17-20 Upgrade Robert W. Baird Neutral → Outperform
Nov-22-19 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19 Downgrade JP Morgan Neutral → Underweight
May-24-19 Initiated Wolfe Research Outperform
Apr-23-19 Upgrade Berenberg Hold → Buy
Dec-13-18 Initiated Berenberg Hold
Jun-06-18 Initiated ROTH Capital Buy
Feb-08-18 Downgrade JP Morgan Overweight → Neutral
Jan-02-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17 Reiterated RBC Capital Mkts Outperform
Sep-15-17 Initiated RBC Capital Mkts Outperform
Jul-11-17 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16 Reiterated Barclays Underweight
Oct-23-15 Downgrade Barclays Equal Weight → Underweight
Oct-23-15 Upgrade JMP Securities Mkt Perform → Mkt Outperform
View All

Enanta Pharmaceuticals Inc Stock (ENTA) Latest News

pulisher
Jul 23, 2025

What analysts say about Enanta Pharmaceuticals Inc. stockSky-high return potential - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Enanta Pharmaceuticals Inc. stock priceTriple-digit growth rates - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Enanta Pharmaceuticals Inc. a good long term investmentHigh-yield capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Enanta Pharmaceuticals Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Enanta Pharmaceuticals at Baird’s Biotech: Strategic Virology and Immunology Shift - Investing.com Canada

Jul 22, 2025
pulisher
Jul 18, 2025

why enanta pharmaceuticals inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFast Growing Stocks - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series - BioSpace

Jul 16, 2025
pulisher
Jul 16, 2025

how enanta pharmaceuticals inc. stock performs during market volatilityFree Smart Investment Opportunities - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

What makes Enanta Pharmaceuticals Inc. stock price move sharplyBreakout Momentum Stocks - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How Enanta Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Enanta Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Spike Monitors - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

(ENTA) On The My Stocks Page - news.stocktradersdaily.com

Jul 12, 2025
pulisher
Jul 10, 2025

Enanta Pharmaceuticals Insider Buyers Net US$65k Despite 11% Stock Decline - simplywall.st

Jul 10, 2025
pulisher
Jun 21, 2025

(ENTA) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 21, 2025
pulisher
Jun 14, 2025

Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 12, 2025

ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 04, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus

Jun 03, 2025

Enanta Pharmaceuticals Inc Stock (ENTA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Cap:     |  Volume (24h):